Table 1 Clinicopathologic features of 1225 patients with primary myelodysplastic neoplasm.
From: A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia
Parameter | Value |
|---|---|
Median age, years (IQR) | 68.4 (57.1–77.4) |
Sex, no. (%) | |
 Male | 778 (63.5%) |
 Female | 447 (36.5%) |
Race | |
 Chinese | 1209 (98.6%) |
 Malay | 8 (0.7%) |
 Japanese | 1 (0.1%) |
 Indian | 3 (0.2%) |
 Filipino | 1 (0.1%) |
 Thai | 1 (0.1%) |
 Vietnamese | 1 (0.1%) |
 Sri Lankan | 1 (0.1%) |
WHO 2016 disease classification, no. (%) | |
 MDS with single lineage dysplasia | 167 (13.6%) |
 MDS with multilineage dysplasia | 297 (24.2%) |
 MDS with ring sideroblasts and single lineage dysplasia | 67 (5.5%) |
 MDS with ring sideroblasts and multilineage dysplasia | 36 (2.9%) |
 MDS with excess blasts-1 | 277 (22.6%) |
 MDS with excess blasts-2 | 317 (25.9%) |
 MDS with isolated del(5q) | 12 (1%) |
 MDS, unclassifiable | 52 (4.2%) |
WHO 2022 disease classification, n. (%) | |
 MDS with low blast and 5q deletion | 17 (1%) |
 MDS with low blast and SF3B1 mutation | 77 (6.3%) |
 MDS with biallelic TP53 inactivation | 118 (9.6%) |
 MDS with low blasts | 505 (41.2%) |
 MDS-IB1 | 223 (18.2%) |
 MDS-IB2 | 285 (23.3%) |
Hematological characteristics at diagnosis | |
 Median white blood cell count, × 109/L (IQR) | 3.3 (2.2–5.3) |
 Median hemoglobin, g/dL (IQR) | 8.3 (6.9–9.5) |
 Median platelet count, × 109/L (IQR) | 82 (39–159) |
 Median absolute neutrophil count, × 109/L (IQR) | 1.50 (0.8–2.8) |
 Median peripheral blood blast percentage (IQR) | 0 (0–1) |
 Median bone marrow blast percentage (IQR) | 4 (1.2–9) |
IPSS-R cytogenetic risk group, no. (%) | |
 Very Good (-Y, del(11q)) | 20 (1.6%) |
 Good (normal, del(5q),del(12p),del(20q),del(5q)+1 additional) | 619 (50.5%) |
 Intermediate (del(7q),+8, + 19,i(17q), others not in other groups) | 241 (19.7%) |
 Poor (-7, inv(3)/t(3q)/del(3q),-7/del(7q)+1 additional) complex (3 abnormalities)) | 70 (5.7%) |
 Very poor (Complex > 3 abnormalities) | 193 (15.8%) |
 Missing due to poor growth | 82 (6.7%) |
IPSS-R risk category, no. (%) | |
 Very low | 49 (4%) |
 Low | 281 (22.9%) |
 Intermediate | 279 (22.8%) |
 High | 259 (21.1%) |
 Very high | 269 (22.0%) |
 Missing information | 88 (7.2%) |
IPSS-M risk category, no (%) | |
 Very low | 1 (0.1%) |
 Low | 36 (2.9%) |
 Moderately low | 55 (4.5%) |
 Moderately high | 81 (6.6%) |
 High | 245 (20%) |
 Very high | 670 (54.7%) |
 Missing information | 137 (11.2%) |
Number of patients who received HMA, no. (%) | 397 (32.4%) |
Azacitidine, no. (%) | 370 (30.2%) |
Decitabine, no (%) | 27 (2.2%) |
Number of patients who received intensive chemotherapy (%) | 126 (10.3%) |
Number of patients who received allogeneic HSCT, no. (%) | 158 (12.9%) |
Transformation to secondary AML, no. (%) | 284 (23.2%) |
Median time to AML transformation, years (IQR) | 1.7 (0.5–5.5) |
Number of deaths, no. (%) | 693 (56.6%) |
Median duration of follow-up, years (IQR) | 2.9 (1–7.1) |
